These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30413372)

  • 41. The Beneficial Effects of P2X7 Antagonism in Rats with Bile Duct Ligation-induced Cirrhosis.
    Tung HC; Lee FY; Wang SS; Tsai MH; Lee JY; Huo TI; Huang HC; Chuang CL; Lin HC; Lee SD
    PLoS One; 2015; 10(5):e0124654. PubMed ID: 25933224
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A selective cyclo-oxygenase-2 inhibitor, NS-398, may improve portal hypertension without inducing gastric mucosal injury.
    Tsugawa K; Hashizume M; Migou S; Kishihara F; Kawanaka H; Tomikawa M; Sugimachi K
    J Gastroenterol Hepatol; 1999 Jul; 14(7):642-51. PubMed ID: 10440208
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Amelioration of portal hypertension and the hyperdynamic circulatory syndrome in cirrhotic rats by neuropeptide Y via pronounced splanchnic vasoaction.
    Moleda L; Trebicka J; Dietrich P; Gäbele E; Hellerbrand C; Straub RH; Sauerbruch T; Schoelmerich J; Wiest R
    Gut; 2011 Aug; 60(8):1122-32. PubMed ID: 21317421
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of nitric oxide and endothelin-1 in a portal hypertensive rat model.
    Tsugawa K; Hashizume M; Migou S; Kishihara F; Kawanaka H; Tomikawa M; Tanoue K; Sugimachi K
    Scand J Gastroenterol; 2000 Oct; 35(10):1097-105. PubMed ID: 11099065
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aminoguanidine corrects hyperdynamic circulation without ameliorating portal hypertension and portal hypertensive gastropathy in anesthetized portal hypertensive rats.
    Lee FY; Wang SS; Tsai YT; Lin HJ; Lin HC; Chu CJ; Wu SL; Tai CC; Lee SD
    J Hepatol; 1997 Mar; 26(3):687-93. PubMed ID: 9075678
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Increased endothelin receptor B and G protein coupled kinase-2 in the mesentery of portal hypertensive rats.
    Du QH; Han L; Jiang JJ; Li PT; Wang XY; Jia X
    World J Gastroenterol; 2013 Apr; 19(13):2065-72. PubMed ID: 23599626
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of terlipressin on in vitro vascular hyporeactivity of portal hypertensive rats.
    Heinemann A; Stauber RE
    J Hepatol; 1996 Jun; 24(6):739-46. PubMed ID: 8835750
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Telmisartan relieves liver fibrosis and portal hypertension by improving vascular remodeling and sinusoidal dysfunction.
    Zheng L; Zhao Z; Lin J; Li H; Wu G; Qi X; Lou X; Bao Y; Huo H; Luo M
    Eur J Pharmacol; 2022 Jan; 915():174713. PubMed ID: 34942161
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aliskiren reduces portal pressure in portal hypertensive rats.
    Chang CC; Lee WS; Huang HC; Lee FY; Wang SS; Lin HC; Nong JY; Lee SD
    Eur J Clin Invest; 2012 May; 42(5):526-33. PubMed ID: 22023532
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Enhanced release of nitric oxide in response to changes in flow and shear stress in the superior mesenteric arteries of portal hypertensive rats.
    Hori N; Wiest R; Groszmann RJ
    Hepatology; 1998 Dec; 28(6):1467-73. PubMed ID: 9828208
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling.
    Reiberger T; Payer BA; Schwabl P; Hayden H; Horvatits T; Jäger B; Hummel T; Mitterhauser M; Trauner M; Fuhrmann V; Angermayr B; Peck-Radosavljevic M;
    Liver Int; 2013 Apr; 33(4):561-8. PubMed ID: 23331709
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice.
    Fernandez M; Vizzutti F; Garcia-Pagan JC; Rodes J; Bosch J
    Gastroenterology; 2004 Mar; 126(3):886-94. PubMed ID: 14988842
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sequential Functions of CPEB1 and CPEB4 Regulate Pathologic Expression of Vascular Endothelial Growth Factor and Angiogenesis in Chronic Liver Disease.
    Calderone V; Gallego J; Fernandez-Miranda G; Garcia-Pras E; Maillo C; Berzigotti A; Mejias M; Bava FA; Angulo-Urarte A; Graupera M; Navarro P; Bosch J; Fernandez M; Mendez R
    Gastroenterology; 2016 Apr; 150(4):982-97.e30. PubMed ID: 26627607
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of nitric oxide synthase and cyclooxygenase in hyperdynamic splanchnic circulation of portal hypertension.
    Xu J; Cao H; Liu H; Wu ZY
    Hepatobiliary Pancreat Dis Int; 2008 Oct; 7(5):503-8. PubMed ID: 18842497
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tyrosine kinase inhibition ameliorates the hyperdynamic state and decreases nitric oxide production in cirrhotic rats with portal hypertension and ascites.
    López-Talavera JC; Levitzki A; Martínez M; Gazit A; Esteban R; Guardia J
    J Clin Invest; 1997 Aug; 100(3):664-70. PubMed ID: 9239414
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Deletion of inducible nitric oxide synthase decreases mesenteric vascular responsiveness in portal hypertensive mice.
    Bexis S; Vandeputte C; McCormick PA; Docherty JR
    Eur J Pharmacol; 2004 Sep; 499(3):325-33. PubMed ID: 15381055
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Increased endothelial nitric oxide synthase activity in the hyperemic vessels of portal hypertensive rats.
    Cahill PA; Redmond EM; Hodges R; Zhang S; Sitzmann JV
    J Hepatol; 1996 Sep; 25(3):370-8. PubMed ID: 8895017
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy.
    Jha JC; Gray SP; Barit D; Okabe J; El-Osta A; Namikoshi T; Thallas-Bonke V; Wingler K; Szyndralewiez C; Heitz F; Touyz RM; Cooper ME; Schmidt HH; Jandeleit-Dahm KA
    J Am Soc Nephrol; 2014 Jun; 25(6):1237-54. PubMed ID: 24511132
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phosphorylation of eNOS initiates excessive NO production in early phases of portal hypertension.
    Iwakiri Y; Tsai MH; McCabe TJ; Gratton JP; Fulton D; Groszmann RJ; Sessa WC
    Am J Physiol Heart Circ Physiol; 2002 Jun; 282(6):H2084-90. PubMed ID: 12003815
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunohistochemical localization of vascular endothelial growth factor in the rat portal hypertensive gastropathy.
    Tsugawa K; Hashizume M; Tomikawa M; Migou S; Kawanaka H; Shiraishi S; Sueishi K; Sugimachi K
    J Gastroenterol Hepatol; 2001 Apr; 16(4):429-37. PubMed ID: 11354282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.